Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 25, 2014

View Archived Issues

Combination of GPR40 agonist and GLP-1 agonist improves glucose control in type 2 diabetes

WNT-974, a porcupine inhibitor targeting Wnt signaling in clinical testing

Candidate antidepressant mGlu2 and 3 receptor antagonists identified at Lilly

Development of a mouse model mimicking human ulcerative colitis

Paradigm to conduct genomic analysis to predict response to Tesaro's TSR-011

NuSirt Biopharma initiates phase II study of metformin/leucine combinations

Cardiac-selective sodium current inhibitor discovered at Gilead Sciences

ENSPIRIT trial of custirsen passes interim futility analysis

Heptares uses StaR platform to derive orexin receptor antagonists

Antitope and University College London to generate fully humanized antibodies

AbbVie begins phase I study of ABT-957 in subjects with Alzheimer's disease

Genentech begins phase I study of MOXR-0916 in locally advanced or metastatic solid tumors

Novel anti-HCV MAbs disclosed by Genentech

Researchers in Japan disclose humanized anti-HMGB1 MAbs

FDA grants Insys Therapeutics' cannabidiol orphan drug designation for GBM

Advaxis and Merck & Co. to collaborate on cancer immunotherapy combination trial

Nuvilex's cancer treatment evaluated in preclinical studies for malignant ascites

Enrollment open in phase I study of CB-5083 for relapsed/refractory multiple myeloma

Stanford University begins first-in-human study of Hu5F9-G4 for solid tumors

Vertex patents novel Na channel modulators

Naurex designs a new series of NMDA receptor modulators

DeuteRx divulges new deuterated PPAR-gamma agonists

Latuda launched in the U.K. for schizophrenia

Phase III REGULATE-PCI of Revolixys Kit halted

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...